Our data suggest that testing patients with FLT3-ITD AML for TET2 mutations should be considered before initiation of more selective FLT3-TKI therapy and that the combination of AZA + TKI could be employed as a means to suppress residual LIC. This evidence concerns the gene TET2 and acute myeloid leukemia.